[Highly selective virostatic therapy. Influenza wave could have been stopped].
Identifieur interne : 000530 ( Main/Corpus ); précédent : 000529; suivant : 000531[Highly selective virostatic therapy. Influenza wave could have been stopped].
Auteurs : Melanie Leshel-HauzenederSource :
- MMW Fortschritte der Medizin [ 1438-3276 ] ; 2003.
English descriptors
- KwdEn :
- Acetamides (administration & dosage), Acetamides (therapeutic use), Antiviral Agents (administration & dosage), Antiviral Agents (therapeutic use), Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Cytokines (blood), Endothelium, Vascular (physiopathology), Enzyme Inhibitors (administration & dosage), Enzyme Inhibitors (therapeutic use), Fibrinogen (analysis), Germany (epidemiology), Humans, Influenza, Human (blood), Influenza, Human (complications), Influenza, Human (drug therapy), Influenza, Human (epidemiology), Influenza, Human (mortality), Influenza, Human (physiopathology), Neuraminidase (administration & dosage), Neuraminidase (antagonists & inhibitors), Oseltamivir, Placebos, Time Factors, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Acetamides, Antiviral Agents, Enzyme Inhibitors, Neuraminidase.
- chemical , analysis : Fibrinogen.
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , blood : Cytokines.
- chemical , therapeutic use : Acetamides, Antiviral Agents, Enzyme Inhibitors.
- geographic , epidemiology : Germany.
- blood : Influenza, Human.
- complications : Influenza, Human.
- drug therapy : Influenza, Human.
- epidemiology : Influenza, Human.
- mortality : Influenza, Human.
- physiopathology : Endothelium, Vascular, Influenza, Human.
- Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Humans, Oseltamivir, Placebos, Time Factors, Treatment Outcome.
PubMed: 15101538
Links to Exploration step
pubmed:15101538Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Highly selective virostatic therapy. Influenza wave could have been stopped].</title>
<author><name sortKey="Leshel Hauzeneder, Melanie" sort="Leshel Hauzeneder, Melanie" uniqKey="Leshel Hauzeneder M" first="Melanie" last="Leshel-Hauzeneder">Melanie Leshel-Hauzeneder</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:15101538</idno>
<idno type="pmid">15101538</idno>
<idno type="wicri:Area/Main/Corpus">000530</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000530</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Highly selective virostatic therapy. Influenza wave could have been stopped].</title>
<author><name sortKey="Leshel Hauzeneder, Melanie" sort="Leshel Hauzeneder, Melanie" uniqKey="Leshel Hauzeneder M" first="Melanie" last="Leshel-Hauzeneder">Melanie Leshel-Hauzeneder</name>
</author>
</analytic>
<series><title level="j">MMW Fortschritte der Medizin</title>
<idno type="ISSN">1438-3276</idno>
<imprint><date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (administration & dosage)</term>
<term>Acetamides (therapeutic use)</term>
<term>Antiviral Agents (administration & dosage)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Clinical Trials, Phase II as Topic</term>
<term>Clinical Trials, Phase III as Topic</term>
<term>Cytokines (blood)</term>
<term>Endothelium, Vascular (physiopathology)</term>
<term>Enzyme Inhibitors (administration & dosage)</term>
<term>Enzyme Inhibitors (therapeutic use)</term>
<term>Fibrinogen (analysis)</term>
<term>Germany (epidemiology)</term>
<term>Humans</term>
<term>Influenza, Human (blood)</term>
<term>Influenza, Human (complications)</term>
<term>Influenza, Human (drug therapy)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (mortality)</term>
<term>Influenza, Human (physiopathology)</term>
<term>Neuraminidase (administration & dosage)</term>
<term>Neuraminidase (antagonists & inhibitors)</term>
<term>Oseltamivir</term>
<term>Placebos</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Acetamides</term>
<term>Antiviral Agents</term>
<term>Enzyme Inhibitors</term>
<term>Neuraminidase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Fibrinogen</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Cytokines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetamides</term>
<term>Antiviral Agents</term>
<term>Enzyme Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Germany</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Endothelium, Vascular</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials, Phase II as Topic</term>
<term>Clinical Trials, Phase III as Topic</term>
<term>Humans</term>
<term>Oseltamivir</term>
<term>Placebos</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15101538</PMID>
<DateCompleted><Year>2005</Year>
<Month>05</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1438-3276</ISSN>
<JournalIssue CitedMedium="Print"><Volume>145</Volume>
<Issue>13</Issue>
<PubDate><Year>2003</Year>
<Month>Mar</Month>
<Day>27</Day>
</PubDate>
</JournalIssue>
<Title>MMW Fortschritte der Medizin</Title>
<ISOAbbreviation>MMW Fortschr Med</ISOAbbreviation>
</Journal>
<ArticleTitle>[Highly selective virostatic therapy. Influenza wave could have been stopped].</ArticleTitle>
<Pagination><MedlinePgn>54-5</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leshel-Hauzeneder</LastName>
<ForeName>Melanie</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>ger</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Hochselektive Virostatikatherapie. Grippewelle hätte gestoppt werden können.</VernacularTitle>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>MMW Fortschr Med</MedlineTA>
<NlmUniqueID>100893959</NlmUniqueID>
<ISSNLinking>1438-3276</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000081">Acetamides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010919">Placebos</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>20O93L6F9H</RegistryNumber>
<NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9001-32-5</RegistryNumber>
<NameOfSubstance UI="D005340">Fibrinogen</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005340" MajorTopicYN="N">Fibrinogen</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>4</Month>
<Day>23</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>5</Month>
<Day>10</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>4</Month>
<Day>23</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15101538</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=ExplorPubmed/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000530 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000530 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= *** parameter Area/wikiCode missing *** |area= ExplorPubmed |flux= Main |étape= Corpus |type= RBID |clé= pubmed:15101538 |texte= [Highly selective virostatic therapy. Influenza wave could have been stopped]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:15101538" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ExplorPubmed
![]() | This area was generated with Dilib version V0.6.35. | ![]() |